BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138. Several additional patients have been screened for enrollment in the trial, a multicenter, open-label, dose-escalation and dose-expansion study of TTX-MC138.
Read more at globenewswire.comTransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TRANSCODE THERAPEUTICS INC
NASDAQ:RNAZ (2/7/2025, 8:00:01 PM)
After market: 10.02 +0.16 (+1.62%)9.86
-1.51 (-13.28%)
RNAZ Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving on Thursday?Curious about what's happening in today's session? Check out the latest stock movements and price changes.
2 days ago - ChartmillThursday's session: top gainers and losersLooking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
2 days ago - ChartmillWhich stocks are moving before the opening bell on Thursday?As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
3 days ago - ChartmillHere are the top movers in Wednesday's session.Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
